Journal of Huntington s Disease · 2022 · 14 citations · 72 references
Life SciencesNeurologyNeuroscienceNeurochemistryNeurodegenerationNeuropathologyBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersHuntington DiseaseMolecular Basis Of NeurodegenerationNeurodegenerative DiseasesNeurodegenerative DisordersCorpus Callosum AbnormalitiesHuntingtin ProteinHuntington Disease BiomarkersHuntington's Disease ModelsNeurological Status AssessmentWhite Matter AnatomyWhite Matter InvolvementWhite Matter Microstructure
BACKGROUND: Huntington's disease (HD) is a fatal neurodegenerative autosomal dominant disorder with prevalence of 1 : 20000 that has no effective treatment to date. Translatability of candidate therapeutics could be enhanced by additional testing in large animal models because of similarities in brain anatomy, size, and immunophysiology. These features enable realistic pre-clinical studies of biodistribution, efficacy, and toxicity. OBJECTIVE AND METHODS: Here we non-invasively characterized alterations in brain white matter microstructure, neurochemistry, neurological status, and mutant Huntingtin protein (mHTT) levels in cerebrospinal fluid (CSF) of aged OVT73 HD sheep. RESULTS: Similar to HD patients, CSF mHTT differentiates HD from normal sheep. Our results are indicative of a decline in neurological status, and alterations in brain white matter diffusion and spectroscopy metric that are more severe in aged female HD sheep. Longitudinal analysis of aged female HD sheep suggests that the decline is detectable over the course of a year. In line with reports of HD human studies, white matter alterations in corpus callosum correlates with a decline in gait of HD sheep. Moreover, alterations in the occipital cortex white matter correlates with a decline in clinical rating score. In addition, the marker of energy metabolism in striatum of aged HD sheep, shows a correlation with decline of clinical rating score and eye coordination. CONCLUSION: This data suggests that OVT73 HD sheep can serve as a pre-manifest large animal model of HD providing a platform for pre-clinical testing of HD therapeutics and non-invasive tracking of the efficacy of the therapy.
72
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
Marian DiFiglia, Ellen Sapp, Kathryn Chase et al. · Science · 1997 · 2.9K citations
A polymorphic DNA marker genetically linked to Huntington's disease
James F. Gusella, Nancy S. Wexler, P. Michael Conneally et al. · Nature · 1983 · 2.3K citations
Unified Huntington's disease rating scale: Reliability and consistency
Movement Disorders · 1996 · 2.1K citations